ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1871

Characterization of Symptoms of Nasal Disease in Relapsing Polychondritis Using Patient-Reported Data

Shubhasree Banerjee1, Nancy Linn2, nathalie costedoat-Chalumeau3, Guillaume Moulis4, Peter Merkel1, Peter Grayson5 and Marcela Ferrada6, 1University of Pennsylvania, Philadelphia, PA, 2Relapsing Polychondritis Foundation Inc., New York, NY, 3Inserm DR Paris 5, Paris, France, 4Toulouse University Hopital, Toulouse, France, 5National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 6National Institutes of Health, Bethesda, MD

Meeting: ACR Convergence 2021

Keywords: nasal chondritis, Patient reported outcomes, relapsing polychondritis, symptoms

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Nasal chondritis is a well-recognized manifestation of relapsing polychondritis (RP), occasionally leading to saddle nose deformity. Early symptoms of nasal chondritis such as nose pain are often overlooked. The objective of this study was to characterize nose pain and identify associated symptoms reported by patients with RP.

Methods: Patients with self-reported RP were invited to participate in an online survey. Participants were asked questions about nose pain such as location, onset, duration, frequency, quality, diurnal variation, aggravating and alleviating factors, associated symptoms, and saddle nose deformity. Participants with physician-diagnosed RP, aged ≥ 18 years, who meet McAdams diagnostic criteria were included in the study. Fisher’s exact test was used to compare clinical characteristics between patients with and without nose pain.

Results: A total of 659 subjects were included, of which 484 (73%) were from the United States. The majority (n=548, 83%) identified themselves as Caucasians, and 574 (87%) were female. Mean age was 50 years (interquartile range = 41-58). Many patients (n=430, 65%) reported nose pain. RP diagnosis was commonly made by rheumatologists (n=313,73%) and otolaryngologists (101, 23%) in patients with nose pain. Compared to patients without nose pain, those with nose pain were more likely to report saddle nose deformity, audio vestibular symptoms, joint pain and swelling (Table 1). Treatment with prednisone was reported by 429 (99%) patients, of which 423 (99%) reported symptom relief with prednisone.

In patients with nose pain (n=430), pain was described as stabbing (n=147, 34%), sharp (n=73, 17%), dull (n=73, 17%), or burning (n=46, 10%); majority (n=313, 73%) reported at least two types of pain and (n=137, 32%) did not report a pain descriptor. Associated nasal pressure (n=150, 34%), tingling (n=119, 27%), or throbbing (n=61, 14%) was reported. Factors felt to aggravate nose pain were minimal trauma (n=240, 55%), stress (n=210, 48%), and cold exposure (n= 104, 24%); 50% reported more than one aggravating factor. Majority (n=322, 75%) reported the pain lasted for ≥1day. Frequency of reported nasal symptoms were daily (n=65, 15%), weekly (n=73, 17%), monthly (n=83, 19%), and few times/year (n=109, 25%). Onset of pain was mostly reported as variable (n=127, 30%) or gradual (n=138, 32%). The location of pain included bridge of the nose (n=252, 58%), sides (n=171, 39%), the base (n=146, 34%), or the tip (n=134, 31%) with 275 (64%) reporting pain in at least two locations. Many patients reported nose pain during the day (n=262, 60%), some reported nighttime pain (n=169, 39%) and pain during sleep (n=108, 25%). Most common associated symptoms were redness, swelling, and congestion, each reported by 50% of patients with nose pain.

Conclusion: Most patients with RP reported a wide range of symptoms of nasal disease. Commonest nasal complaints were stabbing pain with associated redness, swelling and congestion that lasts longer than a day, involves the bridge of the nose, and is aggravated by minor trauma. Detailed assessment of nasal manifestations could be helpful for clinicians for establishing a diagnosis and monitoring disease activity.


Disclosures: S. Banerjee, None; N. Linn, None; n. costedoat-Chalumeau, None; G. Moulis, Amgen, 5, Novartis, 1; P. Merkel, AbbVie, 2, 5, AstraZeneca, 2, 5, Boeringher-Ingelheim, 2, 5, Bristol-Myers Squibb, 2, 5, ChemoCentryx, 2, 5, CSL Behring, 2, Dynacure, 2, Eicos, 2, EMDSerono, 2, Forbius, 2, 5, Genentech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GlaxoSmithKline, 2, 5, InflaRx, 2, 5, Jannsen, 2, Kiniksa, 2, Magenta, 2, Neutrolis, 2, Novartis, 2, Pfizer, 2, Sanofi, 5, Star Therapeutics, 2, Takeda, 2, Talaris, 2, UpToDate, 9; P. Grayson, None; M. Ferrada, None.

To cite this abstract in AMA style:

Banerjee S, Linn N, costedoat-Chalumeau n, Moulis G, Merkel P, Grayson P, Ferrada M. Characterization of Symptoms of Nasal Disease in Relapsing Polychondritis Using Patient-Reported Data [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/characterization-of-symptoms-of-nasal-disease-in-relapsing-polychondritis-using-patient-reported-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-symptoms-of-nasal-disease-in-relapsing-polychondritis-using-patient-reported-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology